Articles tagged "Co-stimulation"

2016 American Transplant Congress
Absence of Host CD137 Signaling Converts Chronic GVHD Toward Acute GVHD.
H. Cho,^1,3 J. Lee,^1,4 J. Kim,¹ U. Moon,¹ B. Kwon,^1,2 S. Park,³ K. Park.⁴
¹Biomedical Research Center, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan, Republic of Korea; ²School of Biological Sciences, University of Ulsan, Ulsan, Republic of Korea; ³Department of Surgery, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan, Republic of Korea; ⁴Department of Internal Medicine, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan, Republic of Korea.
CD137 functions mainly as a costimulatory molecule for T cell activation. However, its functions have been found in a variety of other immune and nonimmune…
2016 American Transplant Congress
Long-Lasting Skin Allograft Tolerance Induced and Maintained by Short-Term Vascularized Bone Marrow Transplant in a Mouse Model.
C.-H. Lin,¹ M. Anggelia,¹ H.-Y. Cheng,¹ Y.-L. Wang,¹ W.-Y. Chuang,¹ C.-H. Lin,¹ G. Brandacher.²
¹Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan; ²Department of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD.
Background: Accumulating evidences indicate that vascularized bone marrow transplantation (VBMT) plays a critical role in inducing tolerance of vascularized composite allografts (VCA). Recipients with long-term…
2015 American Transplant Congress
CFZ533: Assessment of Immunomodulatory Activity Following Single Doses of a Novel Anti-CD40 mAb in Healthy Volunteers
A. Slade,¹ J. Doucet,² P. Koo,¹ P. Espie,² J. Rush,² C. Tomek,³ J. Klupp.²
¹Novartis Institute for Biomedical Research, East Hanover, NJ; ²Novartis Institute for Biomedical Research, Basel, Switzerland; ³Celerion, Inc, Lincoln, NE.
Blocking the CD40-CD154 pathway has been shown to effectively prolong renal allograft survival in non-human primates. CFZ533 is a novel, fully human, Fc-silent, anti-CD40 monoclonal…
2015 American Transplant Congress
Donor Specific Tolerance Can Be Induced by Donor Bone Marrow Transfer With Activation of Invariant Naturel Killer T Cells
S. Miyairi,¹ T. Hirai,¹ R. Shibahara,¹ K. Omoto,¹ S. Nunoda,² K. Yamazaki,² Y. Ishii,³ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan; ²Cardiovascular Surgery, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan; ³Laboratory of Vaccine Design, RIKEN IMS-RCAI, Yokohama, Japan.
It has been reported that liposomal formulation of a-galactosylceramide(lipo-aGC) could induce antigen specific regulatory T cells (Treg) in vivo when administered with particular antigens. We…
2015 American Transplant Congress
Induction of a Costimulation-Susceptible Repertoire: A Case for Depletional Prior to Belatacept
H. Xu,¹ K. Samy,¹ A. Guasch,² S. Mead,² A. Kirk.¹
¹Surgery, Duke University, Durham, NC; ²Transplant Center, Emory University, Atlanta, GA.
Belatacept offers highly specific costimulation blockade to prevent recipient alloimmune responses with reduced toxicity. However, when applied with nondepletional induction therapy belatacept-based regimens have higher…
2015 American Transplant Congress
Non-Cytoreductive Immunosuppression Prevents Rejection of Vascularized Composite Allografts
B. Oh, G. Furtmüller, M. Fryer, G. Raimondi, D. Cooney, W. Lee, G. Brandacher.
Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United Kingdom.
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss such as an extremity or face. Immunosuppression-free donor-specific immunological tolerance has been successfully…
2015 American Transplant Congress
Belatacept Based Immunosuppression and Incidence of Proteinuria in Kidney Transplant Recipients
R. Villicana, A. Peng, J. Kahwaji, J. Choi, A. Vo, S. Jordan.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Abatacept which is a co-stimulation inhibitor has been suggested to have B7-1 mediated antiproteinuric effects. Belatacept which is another co-stimulation agent has been approved…
2015 American Transplant Congress
Renal Allografts Demonstrate Improved Pathology After Belatacept Therapy
T. Saavedra,¹ O. Opara,¹ R. McLoughlin,¹ B. Philosophe,² C. Drachenberg,¹ M. Weir,¹ S. Bartlett,¹ D. Leeser,¹ J. Bromberg,¹ R. Barth.¹
¹University of Maryland School of Medicine, Baltimore; ²Johns Hopkins University, Baltimore.
Belatacept provides immunosuppression via costimulation blockade and has been associated with improved renal function compared to calcineurin inhibitor based therapies. We developed the Maryland Aggregate…
2015 American Transplant Congress
Virus Induced CD28 Down-Regulation as a Potential Driver of Costimulation Blockade Resistant Rejection
D. Mou,¹ J. Espinosa,¹ L. Stempora,² J. Kwun,² N. Iwakoshi,¹ A. Kirk.²
¹Surgery, Emory University, Atlanta, GA; ²Surgery, Duke University, Durham, NC.
Belatacept, a B7-specific fusion protein, blocks CD28-B7 costimulation and prevents kidney allograft rejection. However, it is ineffective in a sizable minority of patients. Although T…
2015 American Transplant Congress
Costimulation Blockade Prevents Rejection of Vascularized Composite Allografts
B. Oh,¹ G. Furtmüller,¹ M. Fryer,¹ J. Grahammer,² S. Schneeberger,² D. Cooney,¹ W. Lee,¹ G. Brandacher.¹
¹Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria.
[Background] Vascularized composite allotransplantation (VCA) is an emerging new era in transplant medicine and has become a valid therapeutic option after devastating tissue loss. The…